Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Validación Clínica TES HT100 para el Cribado de Lesiones Cerebrales en Pacientes con Traumatismo Craneal Leve o Síntomas Neurológicos (TESCO)

21 de septiembre de 2026 actualizado por: B&B srl

Resultados Clínicos TES HT100 - Validación Clínica del Temnógrafo TES HT100 para el Cribado de Lesiones Cerebrales en Pacientes con Traumatismo Craneal Leve o Síntomas Neurológicos Sospechosos (TESCO)

The goal of this clinical study is to evaluate how accurately and safely the TES HT100 device can identify intracranial abnormalities in adult emergency department patients with mild head trauma or neurological symptoms that are not related to trauma and are not immediately life-threatening. The main questions it aims to answer are:

  • How well does TES HT100 identify patients with intracranial abnormalities compared with head CT, the reference standard?
  • Is TES HT100 safe to use in this patient population?
  • Could TES HT100 help improve patient triage and use of hospital resources in the emergency setting?

Researchers will compare the result of TES HT100 with the head CT report.

Participants will:

  • Be enrolled if they are adults presenting to the emergency department with mild head trauma or selected neurological symptoms
  • Undergo standard clinical assessment and head CT according to usual care
  • Have an additional TES HT100 examination lasting about 5 minutes, performed by trained personnel
  • Be assessed for device performance and any adverse events related to use of the device

Descripción general del estudio

Descripción detallada

This is a prospective, multicenter, open-label clinical investigation evaluating the TES HT100 as a non-invasive adjunctive screening device for detection of intracranial abnormalities in adult Emergency Department patients. The study is being conducted in three centers in Italy and Poland.

TES HT100 is intended for non-invasive detection of endocerebral lesions. The device used in this investigation is TES HT model 100, equipped with software version 1.3 or later and firmware version 1.4 or later, in the same configuration planned for commercialization. The system uses non-ionizing, ultra-low-power electromagnetic waves in the 500-6500 MHz frequency range and provides a binary result indicating the presence or absence of intracranial abnormality. The examination is brief, with an overall duration of about 5 minutes.

The study is designed to evaluate the diagnostic performance and safety of TES HT100 when used in addition to standard emergency care. Participants undergo routine clinical assessment and brain CT according to usual clinical practice, and the TES HT100 examination is performed as an add-on procedure. The reference standard for performance evaluation is the brain CT report. TES HT100 is not intended to replace standard clinical assessment or CT imaging.

To reduce interpretation bias, the TES HT100 examination is performed by trained personnel who do not have access to the CT report at the time of testing, and the radiologist interpreting the CT scan is blinded to the TES HT100 result. TES HT100 examinations are performed within 24 hours before or after CT, according to site workflow.

The investigation plans to enroll approximately 850 participants overall across two clinical cohorts. The study duration is planned to be 30 months. Three TES HT100 devices, one per participating center, will be used under the same qualification and maintenance procedures.

In addition to diagnostic validation against CT, the study includes safety monitoring during device use and an exploratory assessment of the potential clinical utility of TES HT100 in emergency department triage and resource management. The overall objective is to generate clinical evidence on the performance and safety of TES HT100 as a rapid, non-invasive screening support tool in the emergency setting.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

850

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • CE
      • Castel Volturno, CE, Italia, 81030
        • Reclutamiento
        • Pineta Grande Hospital
        • Contacto:
        • Sub-Investigador:
          • Angelo Localzo, Registered Nurse
        • Sub-Investigador:
          • Esaù Russo, Registered Nurse
        • Investigador principal:
          • Adriana Modestina Conte, MD
        • Sub-Investigador:
          • Antonia Sorbo, MD - Radiologist
      • Gdansk, Polonia, 80-952
        • Aún no reclutando
        • Emergency Department, University Clinical Centre, Medical University of Gdańsk
        • Contacto:
          • Paweł Nowicki
          • Número de teléfono: +48 730 505 991
          • Correo electrónico: nowicki.p@wp.pl
        • Investigador principal:
          • Mariusz Siemiński, prof. dr hab. n. med.
      • Katowice, Polonia, 40-635
        • Reclutamiento
        • Emergency Department, Leszek Giec Upper Silesian Medical Centre of the Medical University of Silesia in Katowice
        • Contacto:
        • Investigador principal:
          • Mateusz Majewski, dr n. med.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age greater than 18 years
  • Provision of informed consent
  • Presentation to the Emergency Department with mild head injury, or
  • Presentation to the Emergency Department for non-traumatic neurological symptoms and not in a critical condition, including:
  • syncope
  • spatial disorientation and/or loss of balance
  • speech disturbance and/or facial hemi-paresis
  • visual alterations
  • memory loss and/or confusional state

Exclusion Criteria:

  • Age less than 18 years
  • Pregnant women
  • Metal plates or metal prostheses installed in the skull cap
  • Severe head trauma and/or extensive lacerated-contused areas
  • Critical condition
  • Visible skull fracture
  • Failure or inability to provide signed informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: TES HT100 Examination

All enrolled participants receive standard emergency department evaluation, including head CT according to usual clinical practice, and undergo an additional TES HT100 examination as an add-on procedure. TES HT100 is evaluated against the head CT report used as the reference standard. The study includes adults with mild head injury and adults with neurological symptoms not related to head trauma and not in a critical or life-threatening condition.

A non-invasive, add-on diagnostic examination performed with the TES HT100 device to assess the presence or absence of intracranial abnormality in adult emergency department patients. The device uses ultra-low-power, non-ionizing electromagnetic waves in the 500-6500 MHz range and provides a binary on/off result. The examination lasts about 5 minutes, does not require direct contact with the patient's head, and is performed by trained personnel in addition to standard clinical evaluation and head CT.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diagnostic accuracy of TES HT100 for detection of intracranial abnormalities
Periodo de tiempo: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Diagnostic performance of TES HT100 compared with the head CT report as the reference standard, assessed by ROC-AUC and by sensitivity and specificity for identification of intracranial abnormalities.

At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT
Rate of device-related adverse events
Periodo de tiempo: From TES HT100 examination through study participation completion, an average of 1 year

Incidence and type of adverse events related to the use of TES HT100 during the study.

From TES HT100 examination through study participation completion, an average of 1 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Operator time associated with TES HT100-supported screening
Periodo de tiempo: Day 1

Descriptive evaluation of operator time associated with use of TES HT100 during emergency department screening, based on the number of TES HT100 examinations performed per participant and the approximate duration of each examination (about 5 minutes), as described in the protocol.

Day 1
Procedures associated with TES HT100-supported screening
Periodo de tiempo: Day 1

Descriptive evaluation of workflow-related procedures associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol. This may include patient handling or organizational procedures required during the diagnostic pathway, such as patient transfer to a different bed or room or need for additional staff support.

Day 1
Costs associated with TES HT100-supported screening
Periodo de tiempo: Day 1

Descriptive evaluation of resource use and related cost considerations associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol.

Day 1
Diagnostic performance of TES HT100 in predefined patient subgroups
Periodo de tiempo: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Analysis of TES HT100 diagnostic performance, based on sensitivity and specificity versus head CT, in predefined subgroups, including younger patients, older patients, patients with or without prior injury or brain surgery, and patients with or without neurodegenerative disease.

At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Fabrizio Alfieri, B&B srl

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de diciembre de 2024

Finalización primaria (Estimado)

30 de diciembre de 2026

Finalización del estudio (Estimado)

30 de enero de 2027

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de marzo de 2026

Publicado por primera vez (Actual)

24 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

De-identified participant-level data may be shared upon reasonable request, subject to ethics and institutional approval where applicable and execution of a data sharing agreement. Public sharing is not planned due to confidentiality and consent restrictions.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir